MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 0 09.09.2024 17:18 Fiercebiotech.com MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 jwaldron Mon, 09/09/2024 - 10:18
